Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer

  • Hannah Jörißen1,
  • Nuran Bektas2,
  • Edgar Dahl2,
  • Arndt Hartmann3,
  • Anette ten Haaf2,
  • Stefano Di Fiore4,
  • Hans Kiefer5,
  • Andreas Thess5, 6,
  • Stefan Barth1, 7Email author and
  • Torsten Klockenbring1
Contributed equally
BMC Cancer20099:200

https://doi.org/10.1186/1471-2407-9-200

Received: 16 December 2008

Accepted: 24 June 2009

Published: 24 June 2009

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
16 Dec 2008 Submitted Original manuscript
20 Jan 2009 Reviewed Reviewer Report - Marcello Maggiolini
28 Jan 2009 Reviewed Reviewer Report - Nicolas de Roux
9 Feb 2009 Reviewed Reviewer Report - Harriette Kahn
17 Apr 2009 Author responded Author comments - Edgar Dahl
Resubmission - Version 2
17 Apr 2009 Submitted Manuscript version 2
29 May 2009 Reviewed Reviewer Report - Nicolas de Roux
18 Jun 2009 Author responded Author comments - Edgar Dahl
Resubmission - Version 3
18 Jun 2009 Submitted Manuscript version 3
Publishing
24 Jun 2009 Editorially accepted
24 Jun 2009 Article published 10.1186/1471-2407-9-200

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Fraunhofer IME, Department of Pharmaceutical Product Development, Aachen, Germany
(2)
Molecular Oncology Group, Institute of Pathology, University Hospital of the RWTH Aachen, Aachen, Germany
(3)
Department of Pathology, University Hospital Erlangen, Erlangen, Germany
(4)
Institute for Molecular Biotechnology, RWTH Aachen, Aachen, Germany
(5)
M-fold Biotech, Tübingen, Germany
(6)
Current address: CureVac GmbH, Tübingen, Germany
(7)
Department for Experimental Medicine and Immunotherapy, University Hospital of the RWTH Aachen, Aachen, Germany

Advertisement